IPSC (Century Therapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by IPSC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | Joseph Truitt | Director | A | — | — |
| 2026-09-09 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-09-09 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-09-09 | Gregory Russotti | See Remarks | Sell | — | — |
| 2026-08-18 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-08-05 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-06-15 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-06-15 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-06-15 | Gregory Russotti | See Remarks | Sell | — | — |
| 2026-06-15 | Chad Cowan | Chief Scientific Officer | F | — | — |
| 2026-06-12 | Daphne Quimi | Director | A | — | — |
| 2026-06-12 | Alessandro Riva | Director | A | — | — |
| 2026-06-12 | Kimberly Blackwell | Director | A | — | — |
| 2026-06-12 | Martin Patrick Murphy | Director | A | — | — |
| 2026-06-12 | Han Myung Lee | Director | A | — | — |
| 2026-06-09 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-06-09 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-06-09 | Gregory Russotti | See Remarks | Sell | — | — |
| 2026-05-19 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-05-06 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-04-10 | Martin Patrick Murphy | Director | A | — | — |
| 2026-04-03 | Chad Cowan | Chief Scientific Officer | F | — | — |
| 2026-03-16 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-03-16 | Gregory Russotti | See Remarks | Sell | — | — |
| 2026-03-13 | Chad Cowan | Chief Scientific Officer | F | — | — |
| 2026-03-13 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-03-11 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-03-11 | Gregory Russotti | See Remarks | Sell | — | — |
| 2026-03-10 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-02-18 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2026-02-05 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2026-02-04 | Douglas Carr | SVP Finance & Operations | A | — | — |
| 2026-02-04 | Gregory Russotti | See Remarks | A | — | — |
| 2026-02-04 | Chad Cowan | Chief Scientific Officer | A | — | — |
| 2026-02-04 | Brent Pfeiffenberger | President and CEO | A | — | — |
| 2026-01-06 | Chad Cowan | Chief Scientific Officer | F | — | — |
| 2025-12-29 | Chad Cowan | Chief Scientific Officer | Buy | — | — |
| 2025-12-16 | Brent Pfeiffenberger | President and CEO | Buy | — | — |
| 2025-12-12 | Brent Pfeiffenberger | President and CEO | F | — | — |
| 2025-12-11 | Han Myung Lee | Director | A | — | — |
| 2025-12-10 | Gregory Russotti | See Remarks | Sell | — | — |
| 2025-12-10 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2025-11-24 | Chad Cowan | Chief Scientific Officer | Sell | — | — |
| 2025-11-20 | Brent Pfeiffenberger | President and CEO | Buy | — | — |
| 2025-11-19 | Brent Pfeiffenberger | President and CEO | Sell | — | — |
| 2025-11-05 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| 2025-09-22 | Chad Cowan | Chief Scientific Officer | A | — | — |
| 2025-09-10 | Brent Pfeiffenberger | President and CEO | Sell | — | — |
| 2025-09-10 | Gregory Russotti | See Remarks | Sell | — | — |
| 2025-09-10 | Douglas Carr | SVP Finance & Operations | Sell | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 13,259,905 | — |
| — | 10%+ Owner | 13,080,909 | — |
| — | 10%+ Owner | 12,530,909 | — |
| — | 10%+ Owner | 10,390,600 | — |
| — | 10%+ Owner | 6,955,207 | — |
| — | President and CEO | 3,633,839 | — |
| — | Director | 3,206,380 | — |
| — | Chief Scientific Officer | 1,186,019 | — |
| — | See Remarks | 604,558 | — |
| — | President of R&D | 560,544 | — |
| — | SVP Finance & Operations | 504,565 | — |
| — | Chief Scientific Officer | 256,535 | — |
| — | Chief Financial Officer | 253,533 | — |
| — | Chief Operations Officer | 250,141 | — |
| — | Chief Finanical Officer | 79,648 | — |
| — | Director | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the IPSC quote page; the site-wide leaderboard is on the insider transactions hub.